Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning

Rachel E Rau; Margaret A Goodell

doi:10.1016/j.stem.2019.03.001

Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning

Cell Stem Cell. 2019 Apr 4;24(4):511-512. doi: 10.1016/j.stem.2019.03.001.

Authors

Rachel E Rau¹, Margaret A Goodell²

Affiliations

¹ Department of Pediatrics, Stem Cells and Regenerative Medicine Center, Baylor College of Medicine and Texas Children's Hospital, One Baylor Plaza, Houston, TX 77030, USA.
² Department of Pediatrics, Stem Cells and Regenerative Medicine Center, Baylor College of Medicine and Texas Children's Hospital, One Baylor Plaza, Houston, TX 77030, USA. Electronic address: goodell@bcm.edu.

PMID: 30951659
DOI: 10.1016/j.stem.2019.03.001

Abstract

Hematologic diseases may be among the first clinical targets for therapeutic gene editing. In this issue of Cell Stem Cell, Schiroli et al. (2019) report a thorough, unbiased investigation of the impact of gene editing on hematopoietic stem and progenitor function and offer a clear path forward for editing in multiple tissues and conditions.

Publication types

Comment

MeSH terms

DNA Damage
Gene Editing*
Hematopoietic Stem Cells
Tumor Suppressor Protein p53*

Substances

Tumor Suppressor Protein p53